Chemistry:Selisistat
From HandWiki
Selisistat (EX-527) is an experimental drug which is a potent and selective inhibitor of the SIRT1 protein. It was developed as a potential agent for the treatment of Huntington's disease, but also has potential applications in cancer treatment.[1][2][3][4][5]
References
- ↑ "Investigational drugs for the management of Huntington's disease: are we there yet?". Expert Opinion on Investigational Drugs 23 (12): 1595–1603. December 2014. doi:10.1517/13543784.2014.934807. PMID 25084527.
- ↑ "Therapeutic advances in Huntington's Disease". Movement Disorders 30 (11): 1539–1546. September 2015. doi:10.1002/mds.26331. PMID 26226924.
- ↑ "Small Molecules as SIRT Modulators". Mini Reviews in Medicinal Chemistry 18 (13): 1151–1157. 2018. doi:10.2174/1389557516666160620095103. PMID 27334466.
- ↑ "EX527, a sirtuins 1 inhibitor, sensitizes T-cell leukemia to death receptor-mediated apoptosis by downregulating cellular FLICE inhibitory protein". Cancer Biology & Therapy 25 (1). December 2024. doi:10.1080/15384047.2024.2402588. PMID 39286953.
- ↑ "Selisistat, a SIRT1 inhibitor, enhances paclitaxel activity in luminal and triple-negative breast cancer: in silico, in vitro, and in vivo studies". Journal of Enzyme Inhibition and Medicinal Chemistry 40 (1). December 2025. doi:10.1080/14756366.2025.2458554. PMID 39935420.
 |  |
